Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies. [electronic resource]
Producer: 20210115Description: 5-16 p. digitalISSN:- 1665-2681
- Abatacept -- therapeutic use
- Anti-Bacterial Agents -- therapeutic use
- Azetidines -- therapeutic use
- Benzothiazoles -- therapeutic use
- Bezafibrate -- therapeutic use
- Chalcones -- therapeutic use
- Chenodeoxycholic Acid -- analogs & derivatives
- Cholagogues and Choleretics -- therapeutic use
- Cholangitis, Sclerosing -- drug therapy
- Fecal Microbiota Transplantation
- Fibroblast Growth Factors -- analogs & derivatives
- Gastrointestinal Microbiome
- Humans
- Immunologic Factors -- therapeutic use
- Isoxazoles -- therapeutic use
- Janus Kinase Inhibitors -- therapeutic use
- Liver Cirrhosis, Biliary -- drug therapy
- Peroxisome Proliferator-Activated Receptors -- agonists
- Propionates -- therapeutic use
- Purines -- therapeutic use
- Pyrazoles -- therapeutic use
- Pyrazolones -- therapeutic use
- Pyridones -- therapeutic use
- Receptors, Cytoplasmic and Nuclear -- agonists
- Steroids -- therapeutic use
- Sulfonamides -- therapeutic use
- Tretinoin -- therapeutic use
- Ursodeoxycholic Acid -- therapeutic use
- Ustekinumab -- therapeutic use
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
There are no comments on this title.
Log in to your account to post a comment.